Lymphoma - Clinical Research
11 – 20 of 132
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
- Contribution to journal › Letter
-
Mark
Serious illness conversations and quality of end-of-life care in patients with hematological malignancies-a retrospective quality improvement study
- Contribution to journal › Article
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
(2025) In The Lancet
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
-
Mark
Lymphomas : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(2025) In Annals of Oncology
- Contribution to journal › Article
-
Mark
Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma : a multicentre evaluation of MTV, TLG and Dmax
- Contribution to journal › Article
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
- 2024
-
Mark
Per-Patient Illness Trajectory Analyses
(2024) In Journal of Palliative Medicine
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia☆
- Contribution to journal › Article
